Clinical Trials
39 trialsNCT03377023 2026-04-02
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT02299141 2025-06-24
Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Completed
NCT02496585 2025-04-16
Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01314105 2025-02-13
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT02231164 2025-02-13
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
Boehringer Ingelheim
Phase 3 Terminated
NCT01346540 2025-02-12
A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.
Boehringer Ingelheim
Phase 1 Completed
NCT02300298 2025-02-11
Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy
Boehringer Ingelheim
Phase 1 Completed
NCT02780700 2025-02-03
Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]
Boehringer Ingelheim
Phase 2 Terminated
NCT02902484 2024-06-03
Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Terminated
NCT02399215 2023-12-26
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Roswell Park Cancer Institute
Phase 2 Completed
NCT03287947 2022-08-09
LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma
Wake Forest University Health Sciences
Phase 2 Terminated
NCT02665143 2022-04-08
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
Yale University
Phase 2 Completed
NCT02568449 2021-12-09
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01024920 2021-07-19
Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.
Boehringer Ingelheim
Phase 2 Completed
NCT02393755 2021-07-08
Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT02668393 2021-01-29
Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma
Boehringer Ingelheim
Phase 1 Completed
NCT02234596 2021-01-25
Nintedanib in Patients With Advanced Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02452463 2020-04-06
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
Roswell Park Cancer Institute
Phase 2 Terminated
NCT02389764 2019-07-17
Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01907100 2019-03-18
Nintedanib (BIBF 1120) in Mesothelioma
Boehringer Ingelheim
Phase 2/3 Terminated
NCT02751385 2019-03-14
Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer
Boehringer Ingelheim
Phase 1 Terminated
NCT00805194 2018-12-05
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer
Boehringer Ingelheim
Phase 3 Completed
NCT01669798 2018-10-16
BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
Duke University
Phase 2 Completed
NCT01022853 2018-07-30
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
Boehringer Ingelheim
Phase 1 Completed
NCT01015118 2017-12-07
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Boehringer Ingelheim
Phase 3 Completed
NCT01004003 2017-10-26
Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Boehringer Ingelheim
Phase 2 Completed
NCT01225887 2017-10-09
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
GOG Foundation
Phase 2 Completed
NCT02149108 2017-07-21
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
Boehringer Ingelheim
Phase 3 Completed
NCT01948141 2017-06-08
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
Roswell Park Cancer Institute
Phase 2 Completed
NCT00806819 2017-02-02
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Boehringer Ingelheim
Phase 3 Completed
NCT00710762 2016-08-15
A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00987935 2016-03-10
A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
Boehringer Ingelheim
Phase 2 Completed
NCT01594125 2016-02-12
Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
Boehringer Ingelheim
Phase 1 Completed
NCT00998296 2015-08-19
Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.
Boehringer Ingelheim
Phase 1 Completed
NCT00904839 2015-02-04
BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00706628 2015-01-15
A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
Boehringer Ingelheim
Phase 2 Completed
NCT00715403 2014-12-02
A Phase I/II Open Label Extension Study of BIBF 1120 Administered Orally Once or Twice Daily to Establish Safety, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and Clinical Benefit From Previous Therapy With BIBF 1120
Boehringer Ingelheim
Phase 1 Completed
NCT01329549 2014-11-27
Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC)
Boehringer Ingelheim
Phase 1 Terminated
NCT01380782 2014-08-18
BIBF 1120 for Recurrent High-Grade Gliomas
Dana-Farber Cancer Institute
Phase 2 Completed